checkAd

    EQS-News  148  0 Kommentare Krones AG: Krones expands its capabilities in the growing pharmaceutical market with the acquisition of US company R+D Custom Automation

    EQS-News: Krones AG / Key word(s): Acquisition
    Krones AG: Krones expands its capabilities in the growing pharmaceutical market with the acquisition of US company R+D Custom Automation

    09.11.2022 / 07:30 CET/CEST
    The issuer is solely responsible for the content of this announcement.


     

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Krones AG!
    Long
    112,33€
    Basispreis
    1,15
    Ask
    × 10,58
    Hebel
    Short
    134,71€
    Basispreis
    1,21
    Ask
    × 10,32
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    9 November 2022

    Corporate News Release

     


    Krones expands its capabilities in the growing pharmaceutical market with the acquisition of US company R+D Custom Automation
     

    Krones, a leading manufacturer of filling and packaging solutions, has acquired 80.5% of R+D Custom Automation LLC (R+D) with effect from 8 November 2022. Based in Wisconsin, USA, R+D supplies machinery and equipment for the production and filling of containers for the pharmaceutical industry. As a full-service system integrator and specialised equipment manufacturer, R+D has been providing custom engineering solutions to the life science industry for over 40 years.

    In the 2021 fiscal year, the company generated revenue of some US$43 million with a workforce of more than 60 employees. The purchase price for the stake in R+D is in the mid double-digit millions of US dollars and is met out of available cash funds.

    Krones has an option to buy the remaining 19.5% of the shares in R+D, which remain with the current management.

    The acquisition of R+D marks a continuation of Krones’ strategy of additional growth outside the beverage industry. It strengthens Krones’ activities in the attractive life science and pharmaceutical market, which shows above-average growth. In R+D, Krones also gains a highly experienced team with innovative solutions and good customer relationships with established pharmaceutical groups.

     

     

    Contact:

    Olaf Scholz

    Head of Investor Relations, Krones AG

    Tel.: +49 9401 70-1169

    Email: olaf.scholz@krones.com

     

     



    09.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.eqs-news.com


    Language: English
    Company: Krones AG
    Böhmerwaldstraße 5
    93073 Neutraubling
    Germany
    Phone: +49 (0)9401 701169
    Fax: +49 (0)9401 709 1 1169
    E-mail: investor-relations@krones.com
    Internet: www.krones.com
    ISIN: DE0006335003
    WKN: 633500
    Indices: SDAX
    Listed: Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange
    EQS News ID: 1482587

     
    End of News EQS News Service

    1482587  09.11.2022 CET/CEST

    fncls.ssp?fn=show_t_gif&application_id=1482587&application_name=news&site_id=wallstreet

    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    EQS-News Krones AG: Krones expands its capabilities in the growing pharmaceutical market with the acquisition of US company R+D Custom Automation EQS-News: Krones AG / Key word(s): Acquisition Krones AG: Krones expands its capabilities in the growing pharmaceutical market with the acquisition of US company R+D Custom Automation 09.11.2022 / 07:30 CET/CEST The issuer is solely responsible …

    Schreibe Deinen Kommentar

    Disclaimer